94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Physiol.
Sec. Redox Physiology
Volume 16 - 2025 | doi: 10.3389/fphys.2025.1551932
Hemoglobin-based oxygen carriers, oxidative stress and myocardial infarction
Provisionally accepted- Chart Biotech, LLC, Erie, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Development of hemoglobin-based oxygen carriers (HBOCs) for use as temporary blood replacement solutions and treatment of hemorrhagic shock has been hindered because of evidence HBOC infusion increases the risk of myocardial infarction (MI). To gain insight into potential toxicity mechanisms, MI incidence from later stage clinical testing of five HBOCs was compared to pharmacokinetic and biochemical parameters to identify correlations suggestive of cause-and-effect relationships. There are positive correlations between MI incidence and HBOC dose, size, intravascular half-life and area under the plasma concentration versus time curve (AUC). Furthermore, MI incidence is positively correlated with initial rates of HBOC autoxidation, oxidation by nitric oxide, and AUCs estimated for these HBOC oxidation products. These observations imply that increased MI risk after HBOC infusion is due to intravascular reactions which exacerbate oxidative stress.
Keywords: Hemoglobin-based oxygen carrier, HBOC, Myocardial Infarction, Oxidative Stress, Nitric Oxide, hemoglobin autoxidation, pharmacokinetics, AUC
Received: 26 Dec 2024; Accepted: 11 Mar 2025.
Copyright: © 2025 Estep. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Timothy Estep, Chart Biotech, LLC, Erie, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.